Clinical Scorecard: Immunological and Clinical Features of Extended SARS-CoV-2 Omicron Infections in Patients with Hematologic Disorders
At a Glance
Category
Detail
Condition
Prolonged viral shedding (PVS) of SARS-CoV-2 Omicron variant
Key Mechanisms
Combined depletion of B-cells (CD19+) and CD4+ T-cells, increased exhausted CD4+ T-cells (PD-1high), and reduced neutralizing antibody activity against Omicron subvariants
Target Population
Patients with hematologic disorders, especially those treated with anti-CD20 antibodies and bendamustine
Care Setting
Hospital and outpatient settings managing hematologic patients with breakthrough COVID-19 infection
Key Highlights
13.3% of patients with hematologic disorders developed Omicron breakthrough infection; 28.7% showed prolonged viral shedding (PVS).
PVS associated with significant depletion of CD4+ and CD19+ cells, higher exhausted CD4+ T-cell frequency, and poor neutralizing antibody response to Omicron subvariants.
Patients treated with bendamustine plus anti-CD20 antibodies had the highest risk of PVS and COVID-19-related mortality.
Guideline-Based Recommendations
Diagnosis
Define PVS as SARS-CoV-2 PCR cycle threshold (Ct) < 30 for ≥21 days after symptom onset.
Monitor lymphocyte subsets including CD4+ and CD19+ cell counts in patients with hematologic disorders and COVID-19.
Management
Use ritonavir-boosted nirmatrelvir as initial antiviral therapy in breakthrough infections.
Consider heightened vigilance and tailored antiviral strategies in patients recently treated with anti-CD20 antibodies and bendamustine.
Monitoring & Follow-up
Perform longitudinal SARS-CoV-2 PCR testing to assess viral clearance.
Evaluate T-cell phenotypes focusing on exhaustion markers (PD-1) and activation markers (CD38high/HLA-DRhigh) in persistent infections.
Assess neutralizing antibody activity against Omicron subvariants to guide risk stratification.
Risks
Recent anti-CD20 antibody and bendamustine therapy increase risk of PVS and severe COVID-19 outcomes.
Low CD4+ and CD19+ cell counts and seronegative status post-infection are associated with prolonged viral shedding.
PVS may lead to increased hospitalization and mortality in hematologic patients.
Patient & Prescribing Data
Patients with hematologic disorders experiencing breakthrough SARS-CoV-2 Omicron infection
Ritonavir-boosted nirmatrelvir was the most commonly used antiviral; early antiviral therapy generally resolved infection except in patients with combined B- and CD4+ T-cell depletion or recent immunosuppressive therapy.
Clinical Best Practices
Screen hematologic patients with COVID-19 for prolonged viral shedding using serial PCR Ct values.
Monitor immune cell subsets to identify patients at risk for persistent infection.
Prioritize early antiviral treatment in high-risk patients, especially those with recent anti-CD20 and bendamustine exposure.
Consider immune profiling including T-cell exhaustion markers to understand viral persistence mechanisms.
Evaluate neutralizing antibody responses post-infection to inform prognosis and potential need for additional interventions.
